天津贝罗尼生物科技有限公司人脉圈

贝罗尼集团有限公司是一家集研发、生产、营销于一体的国际化、集团化企业。集团海外研发、生产基地和运营中心在美丽的澳大利亚悉尼，大中华总部设在香港，大中华研发中心和全球营销中心位于美丽的滨海城市天津。 经营业务主要集中于生物科技、生命科学、环境科学和治理、精准医疗、再生医学、基因检测与干细胞防癌抗癌抗衰老项目。 截止2017年12月，公司已获得和正在申请的专利达120项，并荣获“天津市专利试点单位”、“天津市中小型科技企业”称号，“天津市高新技术企业”，“国家高新技术企业”称号。 企业于2017年5月12日在澳大利亚国家证券交易所IPO成功上市，并于2018年1月19日在德国法兰克福证券交易所双挂牌上市，成为中国首家赴澳、赴德两国成功上市的生物科技型企业。 Beroni Group is an international and group enterprise integrating R&D, production and marking. Its oversea R&D centre, production base and operations center are located in Sydney, Australia. The headquarters of the Greater China is set in Hong Kong. R&D centre of the Greater China and global marking center are located in the beautiful coastal city-Tianjin, China. The business of the company is focused on biotechnology, life sciences, environmental science and governance, precision medicine, regeneration medicine, genetic testing, and stem cell anti-cancer and anti-aging projects. Up to December 2017, the company has obtained and is applying for nearly 120 patents. It won the following titles: “Tianjin patent pilot unit”, “small and medium-sized enterprise of science and technology in Tianjin”, “Tianjin high and new technology enterprise”and “national high and new technology enterprise”. On 12th May, 2017, the company formally listed on the National Stock Exchange of Australia, and dual listed on the Frankfurt Stock Exchange on 19th January, 2018, which marked the company has become the first Chinese biotechnological company both listing in Australia and Germany.